×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SRPT – sarepta therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SRPT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
06:32 am
srpt
High Growth Tech Stocks To Watch For Potential Opportunities [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Watch For Potential Opportunities [Yahoo! Finance]
12/20
05:21 am
srpt
High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]
12/20
04:25 am
srpt
High Growth Tech And 2 Other Promising Stocks With Strong Potential [Yahoo! Finance]
Low
Report
High Growth Tech And 2 Other Promising Stocks With Strong Potential [Yahoo! Finance]
12/19
10:12 am
srpt
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder [Yahoo! Finance]
Low
Report
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder [Yahoo! Finance]
12/19
08:10 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "sell" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "sell" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
12/18
08:36 am
srpt
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 [Yahoo! Finance]
Medium
Report
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 [Yahoo! Finance]
12/18
08:30 am
srpt
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Medium
Report
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
12/17
10:30 am
srpt
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 [Yahoo! Finance]
Low
Report
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2024
04:05 pm
SRPT
sarepta therapeutics, inc.
BEAT
Report
-7.4%
sarepta therapeutics, inc.
8/7/2024
04:05 pm
SRPT
sarepta therapeutics, inc.
BEAT
Report
7.7%
sarepta therapeutics, inc.
5/1/2024
04:05 pm
SRPT
sarepta therapeutics, inc.
BEAT
Report
-1.8%
sarepta therapeutics, inc.
2/28/2024
04:05 pm
SRPT
sarepta therapeutics, inc.
BEAT
Report
-8.6%
sarepta therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/16
08:00 pm
srpt
Form 4 Sarepta Therapeutics, For: Dec 12 Filed by: Wigzell Hans Lennart Rudolf
Low
Report
Form 4 Sarepta Therapeutics, For: Dec 12 Filed by: Wigzell Hans Lennart Rudolf
12/12
05:06 pm
srpt
Form 144 Sarepta Therapeutics, Filed by: Wigzell Hans Lennart Rudolf
Low
Report
Form 144 Sarepta Therapeutics, Filed by: Wigzell Hans Lennart Rudolf
12/6
08:01 pm
srpt
Form 4 Sarepta Therapeutics, For: Dec 05 Filed by: Boor Kathryn Jean
Low
Report
Form 4 Sarepta Therapeutics, For: Dec 05 Filed by: Boor Kathryn Jean
12/5
04:19 pm
srpt
Form 144 Sarepta Therapeutics, Filed by: Boor Kathryn Jean
Low
Report
Form 144 Sarepta Therapeutics, Filed by: Boor Kathryn Jean
11/29
08:15 pm
srpt
Form 4 Sarepta Therapeutics, For: Nov 26 Filed by: Rothfuss Cristin
Medium
Report
Form 4 Sarepta Therapeutics, For: Nov 26 Filed by: Rothfuss Cristin
11/29
08:00 pm
srpt
Form 3 Sarepta Therapeutics, For: Nov 26 Filed by: Rothfuss Cristin
Medium
Report
Form 3 Sarepta Therapeutics, For: Nov 26 Filed by: Rothfuss Cristin
11/26
07:18 am
srpt
Form 8-K Sarepta Therapeutics, For: Nov 24
High
Report
Form 8-K Sarepta Therapeutics, For: Nov 24
11/20
08:01 pm
srpt
Form 4 Sarepta Therapeutics, For: Nov 18 Filed by: Rodino-Klapac Louise
Low
Report
Form 4 Sarepta Therapeutics, For: Nov 18 Filed by: Rodino-Klapac Louise
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
Sarepta Therapeutics Inc (NASDAQ: SRPT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
11.5%
2/28 Sarepta Therapeutics Inc (NASDAQ: SRPT) had its price target lowered by analysts at JPMorgan Chase & Co. from $172.00 to $160.00. They now have an "overweight" rating on the stock. 8.1%
12/23 Roche enters $1.15 bln licensing deal for Sarepta gene therapy [Reuters] 7.6%
8/8 Patient in Sarepta gene therapy trial develops serious illness; shares plunge [Reuters] 7.0%
10/31 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 6.7%
12/12 Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 6.5%
9/10 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents at Morgan Stanley 17th Annual Global Healthcare Conference (Transcript) [Seeking Alpha] 6.3%
10/4 Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy 6.0%
11/7 Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments 4.9%
6/4 Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference 4.9%
2/28 Sarepta Therapeutics Inc (NASDAQ: SRPT) had its price target lowered by analysts at JPMorgan Chase & Co. from $172.00 to $160.00. They now have an "overweight" rating on the stock. 8.1%
12/23 Roche enters $1.15 bln licensing deal for Sarepta gene therapy [Reuters] 7.6%
8/8 Patient in Sarepta gene therapy trial develops serious illness; shares plunge [Reuters] 7.0%
10/31 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 6.7%
12/12 Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 6.5%
9/10 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents at Morgan Stanley 17th Annual Global Healthcare Conference (Transcript) [Seeking Alpha] 6.3%
10/4 Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy 6.0%
11/7 Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments 4.9%
6/4 Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference 4.9%
TOP News Decliners
8/19
Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application
-15.0%
3/6 Form 4 Sarepta Therapeutics, For: Mar 04 Filed by: Wigzell Hans Lennart Rudolf -8.6%
10/4 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents Limb-Girdle Muscular Dystrophy Type 2E Functional Results (Transcript) [Seeking Alpha] -8.3%
5/12 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -8.0%
2/26 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments -8.0%
8/21 Pfizer Digs Deeper Into Gene Therapy, Rivaling These Biotech Stocks [Investor's Business Daily] -6.6%
1/22 Sarepta shares fall 4% after FDA documents show safety concern about drug [Reuters] -6.4%
8/7 Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments -5.7%
8/30 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -5.4%
8/8 This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged [Investor's Business Daily] -5.4%
3/6 Form 4 Sarepta Therapeutics, For: Mar 04 Filed by: Wigzell Hans Lennart Rudolf -8.6%
10/4 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents Limb-Girdle Muscular Dystrophy Type 2E Functional Results (Transcript) [Seeking Alpha] -8.3%
5/12 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -8.0%
2/26 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments -8.0%
8/21 Pfizer Digs Deeper Into Gene Therapy, Rivaling These Biotech Stocks [Investor's Business Daily] -6.6%
1/22 Sarepta shares fall 4% after FDA documents show safety concern about drug [Reuters] -6.4%
8/7 Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments -5.7%
8/30 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -5.4%
8/8 This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged [Investor's Business Daily] -5.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: